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Introduction
Spinal muscular atrophy (SMA) is an autosomal-recessive
neuromuscular disorder characterized by motor neuron
degeneration in the anterior horn of the spinal cord and brain
stem, resulting in progressive muscle weakness and atrophy.
The responsible survival motor neuron gene (SMN1; HGNC:
11117) is localized in 5q11.2-13.3. Screening for carriers of
SMA is necessary for effective clinical/prenatal diagnosis
and genetic counselling. In this study, the copy number of
SMN1 gene was determined from a southern Italian popu-
lation to estimate carrier frequency. This is the ﬁrst report
addressing the estimation of SMA carrier frequency in an
Italian population. Our results show that the SMA carrier
frequency in Sicily is higher than in the European popula-
tions and lower than in Mediterranean/Middle Eastern coun-
tries. The carrier testing could be a helpful tool for genetic
counselling, to individuals with a positive family history.
SMA is the second most common severe autosomal-
recessive disorder after cystic ﬁbrosis and the most frequent
genetic cause of infant mortality, with an incidence of one per
6000–10,000 live births (Pearn 1980). Mutations in the sur-
vival motor neuron gene (SMN1; HGNC: 11117), localized
in 5q11.2-13.3 within a large inverted duplicated element,
cause SMA types I, II, III and IV (Lefebvre et al. 1995).
Further, between 95% and 98% of individuals with recessive
SMA have two deletion mutations (deletion of exons 7–8)
and the remaining 2–5% have one deletion mutation (exons
7–8) and a second, different type of mutation (Ogino and
Wilson 2002). People generally have between one and three
copies of the SMN1 gene. Usually, people with two copies
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of SMN1, there is one copy of the gene on each chromo-
some (called ‘1+1’). However, it is also possible for a per-
son to have two SMN1 copies arranged together on the same
chromosome, and no copies on the other chromosome (called
‘2+0’). In this case, the parent is a carrier and is at risk of hav-
ing a child with SMA if a SMN1 mutation was also passed by
the other parent. Dosage analysis cannot predict the differ-
ence between ‘1+1’ and ‘2+0’ arrangements. Both situations
are simply detected as having two SMN1 copies.
Identiﬁcation of SMA carriers has important implications
for effective clinical/prenatal diagnosis and genetic coun-
selling; however, in different populations the carrier frequen-
cy varies widely between 1/20 and 1/125 (Ogino et al.
2004; Hendrickson et al. 2009; Hasanzad et al. 2010;
Sugarman et al. 2012). Caucasians and Ashkenazi Jews
have higher carrier rates than Asians, African Americans
and Hispanics (Hendrickson et al. 2009). Carrier frequen-
cies in Morocco (1/25) and in Iran and Saudi Arabia (1/20)
are higher than in the European populations (from 1/50 to
1/80) (Lyahyai et al. 2012). A population-based study of
SMA prevalence in Italy has not yet been conducted, but
a frequency of the heterozygote of 1/57 has been inferred
in a northeastern Italian (Veneto) population (Mostacciuolo
et al. 1992).
The present work was carried out to calculate the carrier
frequency of deletion of SMN1 exons 7–8 among the general
population of Sicily and to estimate the prevalence of SMA
in the study population.
Method
The project was approved by the local Institution Ethics
Committee. Four hundred and ﬁfty unrelated noncon-
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Table 1. Frequencies, average values RPA ratio, range and standard deviation showed by each probe speciﬁc for the MLPA P021 analysis
of SMA critical region in the group of 450 normal controls.
SMN1 gene Frequency Average values Minimum/maximum
(HGNC: 11117) Gene copy number N = 450 (%) RPA ratio values RPA ratio SD
Exon 7 2 copies (1+1 or 2+0)* 409 90.89 1.00 0.73–1.25 0.08
Exon 8 2 copies (1+1 or 2+0)* 409 90.89 0.99 0.67–1.25 0.10
Exon 7 1 copy (1+0) 13 2.89 0.54 0.47–0.64 0.05
Exon 8 1 copy (1+0) 13 2.89 0.52 0.43–0.62 0.06
Exon 7 3 copies (2+1) 28 6.22 1.49 1.32–1.63 0.09
Exon 8 3 copies (2+1) 28 6.22 1.46 1.30–1.62 0.09
*MLPA SMN1 copy number analysis is not able to differentiate the two genotypes.
sanguineous healthy individuals from Sicily (Italy) were
selected for this study. Informed consent was obtained
from each subject. The multiplex ligation-dependent probe
ampliﬁcation (MLPA) was performed using the SALSA
P021 kit, from MRC-Holland (Amsterdam, The Netherlands;
www.mrc-holland.com). This kit contains a probe mixture
for SMN1 exons 7 and 8 (SMN1; HGNC: 11117), SMN2
exons 7 and 8 (SMN2; HGNC: 11118) and several con-
trol fragments located on different chromosomes. All reac-
tions were carried out according to the manufacturer’s rec-
ommendations (www.mlpa.com). Approximately 200 ng of
genomic DNA was used for the MLPA reaction. The MLPA
products were analysed using an ABI 3130 Genetic Anal-
yser (Applied Biosystems, Foster City, USA), with Gene-
Scan ROX 500. To process the MLPA deletion/duplication
data efﬁciently, a spreadsheet was generated using Microsoft
Excel software. First, the data corresponding to each DNA
control sample were normalized by dividing each probe’s
signal strength (i.e., the area of each peak) by the average
signal strength yielded by the 21 control probes to generate
for each peak a relative peak area (RPA) value. The RPA
value for each probe in the sample was then compared to
that of 50 negative samples. The latter ratio was then used
to deﬁne the following categories: (i) ∼1.0 for the non-
deleted/nonduplicated gene region, (ii) ∼0.5 if deleted in
heterozygote status, and (iii) ∼1.5 if duplicated. We com-
puted the standard deviation (SD) of the normalized signals
of mean RPA ratio relative to each group (1 copy, 2 and 3
copies) (see table 1). MLPA analysis was repeated for sam-
ples yielding a SD exceeding the threshold value of 0.1. Such
value approximatively corresponds to the mean value of the
standard deviations of the normalized data relative to the
probes of all considered individuals. Other details on normal-
izing and quality test are as described in Calì et al. (2010).
All tests that gave a result consistent with one (carrier) or
three copies of exons 7–8 of SMN1 gene, were retested using
a comparative multiplex dosage analysis (CMDA) protocol
as described in Saugier-Veber et al. (2001).
Results and discussion
The screening results, frequency, mean RPA ratio, range and
standard deviation are shown in table 1. All positive to one
(carrier) or three copies of exons 7–8 of SMN1 gene were
conﬁrmed using CMDA test (data not shown). Thirteen of
the 450 healthy individuals were found to be SMA carri-
ers, with SMN1 exons 7–8 deletion yielding a real carrier
prevalence of 1:34 (∼3%, table 1). Three copies of SMN1
exons 7–8 were detected in 28 individuals (∼6%, table 1).
However, few of 409/450 individuals (table 1) having two
SMN1 exons 7–8 copies may still be deletion carriers (2+0
genotype) (see Introduction). This fact highlights the limi-
tation of all quantitative SMN1 analyses that underestimate
the SMA carrier rate and has serious genetic counselling
implications.
Assuming Hardy–Weinberg equilibrium, this carrier fre-
quency (1:34) would mean a calculated SMA prevalence of
1/4793. Given that the average number (between years 2002
and 2010) of children born in Sicily is around 50,000 per year
(data from ISTAT, http://www.istat.it/), there could be about
10 individuals (each year) with SMN1 homozygous deletion
and SMA phenotype, considering no deaths. Our results also
show that the carrier frequencies of SMA among Sicilian
healthy individuals is higher than in the European popula-
tions and lower then in Mediterranean/Middle Eastern coun-
tries, probably determined by genetic ﬂows that occurred into
the island, due to ancient Mediterranean colonization and
to northern African contributions (Di Gaetano et al. 2009).
The present study was carried out to estimate the carrier fre-
quency of copy number changes of exons 7–8 of the SMN1
gene among the Sicilian population (Italy) taking in account
that the method used could detect approximately 95–98%
of carriers. This is the ﬁrst report addressing the estimation
of SMA carrier frequency in an Italian population, based
on a sample of 450 nonrelated healthy individuals. The car-
rier testing could be a helpful tool for genetic counselling
particularly in families with a clear clinical history of SMA.
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